Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Ibodutant> ?p ?o }
Showing triples 1 to 88 of
88
with 100 triples per page.
- Ibodutant abstract "Ibodutant is a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it is undergoing a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe(the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study in women is ongoing.".
- Ibodutant atcPrefix "none".
- Ibodutant fdaUniiCode "1H7RSQ28BJ".
- Ibodutant iupacName "Nα-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-N-{[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]methyl}-(D)-phenylalaninamide".
- Ibodutant pubchem "11527495".
- Ibodutant thumbnail Ibodutant_structure.svg?width=300.
- Ibodutant wikiPageID "19012257".
- Ibodutant wikiPageLength "3599".
- Ibodutant wikiPageOutDegree "15".
- Ibodutant wikiPageRevisionID "682568818".
- Ibodutant wikiPageWikiLink Category:Amides.
- Ibodutant wikiPageWikiLink Category:Benzothiazoles.
- Ibodutant wikiPageWikiLink Category:NK2_receptor_antagonists.
- Ibodutant wikiPageWikiLink Category:Piperidines.
- Ibodutant wikiPageWikiLink Category:Pyrans.
- Ibodutant wikiPageWikiLink Category:Tachykinin_receptor_antagonists.
- Ibodutant wikiPageWikiLink Clinical_trial.
- Ibodutant wikiPageWikiLink GR-159,897.
- Ibodutant wikiPageWikiLink Irritable_bowel_syndrome.
- Ibodutant wikiPageWikiLink Menarini.
- Ibodutant wikiPageWikiLink Molar_concentration.
- Ibodutant wikiPageWikiLink Nepadutant.
- Ibodutant wikiPageWikiLink Saredutant.
- Ibodutant wikiPageWikiLink Tachykinin_receptor.
- Ibodutant wikiPageWikiLink Tachykinin_receptor_2.
- Ibodutant wikiPageWikiLinkText "Ibodutant".
- Ibodutant wikiPageWikiLinkText "ibodutant".
- Ibodutant atcPrefix "none".
- Ibodutant c "37".
- Ibodutant chemspiderid "9702281".
- Ibodutant h "48".
- Ibodutant inchi "1".
- Ibodutant inchikey "YQYSVMKCMIUCHY-WJOKGBTCBH".
- Ibodutant iupacName "Nα-[carbonyl]-N-{[1-piperidin-4-yl]methyl}-(D)-phenylalaninamide".
- Ibodutant iupharLigand "2117".
- Ibodutant molecularWeight "644.866".
- Ibodutant n "4".
- Ibodutant o "4".
- Ibodutant pubchem "11527495".
- Ibodutant routesOfAdministration "Oral".
- Ibodutant s "1".
- Ibodutant smiles "CC1=CC2=CC=CCNC3CNCCNCC5CCNCC6CCOCC6".
- Ibodutant stdinchi "1".
- Ibodutant stdinchikey "YQYSVMKCMIUCHY-WJOKGBTCSA-N".
- Ibodutant synonyms "6".
- Ibodutant unii "1".
- Ibodutant verifiedfields "changed".
- Ibodutant verifiedrevid "444434892".
- Ibodutant width "150".
- Ibodutant wikiPageUsesTemplate Template:As_of.
- Ibodutant wikiPageUsesTemplate Template:Chemspidercite.
- Ibodutant wikiPageUsesTemplate Template:Cite_journal.
- Ibodutant wikiPageUsesTemplate Template:Drugbankcite.
- Ibodutant wikiPageUsesTemplate Template:Drugbox.
- Ibodutant wikiPageUsesTemplate Template:Fdacite.
- Ibodutant wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- Ibodutant wikiPageUsesTemplate Template:Neuropeptidergics.
- Ibodutant wikiPageUsesTemplate Template:Reflist.
- Ibodutant wikiPageUsesTemplate Template:Stdinchicite.
- Ibodutant subject Category:Amides.
- Ibodutant subject Category:Benzothiazoles.
- Ibodutant subject Category:NK2_receptor_antagonists.
- Ibodutant subject Category:Piperidines.
- Ibodutant subject Category:Pyrans.
- Ibodutant subject Category:Tachykinin_receptor_antagonists.
- Ibodutant hypernym Drug.
- Ibodutant type ChemicalSubstance.
- Ibodutant type Drug.
- Ibodutant type Group.
- Ibodutant type Amide.
- Ibodutant type Antagonist.
- Ibodutant type Chemical.
- Ibodutant type Drug.
- Ibodutant type Group.
- Ibodutant type Heterocycle.
- Ibodutant type ChemicalObject.
- Ibodutant type Thing.
- Ibodutant type Q8386.
- Ibodutant comment "Ibodutant is a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it is undergoing a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe(the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study in women is ongoing.".
- Ibodutant label "Ibodutant".
- Ibodutant sameAs Q5984345.
- Ibodutant sameAs m.04jj7v6.
- Ibodutant sameAs Ibodutant.
- Ibodutant sameAs Ibodutant.
- Ibodutant sameAs Q5984345.
- Ibodutant wasDerivedFrom Ibodutant?oldid=682568818.
- Ibodutant depiction Ibodutant_structure.svg.
- Ibodutant isPrimaryTopicOf Ibodutant.